The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: Iodine-123-iodobenzamide single photon emission computed tomography study

Psychiatry Research - Neuroimaging

Volumn 201, Issue 1, 2012, Pages 73-77

  Corripio, Iluminada ^a   Ferreira, Alcides ^a,b   Portella, Maria J ^a   Pérez, Víctor ^a   Escartí, María J ^c   del Valle Camacho, Maria ^d   Sauras, Rosa B ^a   Alonso, Anna ^a   Grasa, Eva Ma ^a   Carrió, Ignasi ^d   Catafau, Ana M ^e   Álvarez, Enric ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Adult Mental Health Center Horta Guinardó   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Barcelona Imaging Group   (Spain)

Author keywords

Antipsychotics; Dopaminergic receptors; Extrapyramidal side effects; IBZM SPECT

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; IOLOPRIDE I 123; OLANZAPINE; PERCHLORATE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NEUROIMAGING; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CORPUS STRIATUM; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84857448446     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2011.02.004     Document Type: Article

References (45)

1. Abi-Dargham A., Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003, 9(5):404-416.
2. Agid O., Mamo D., Ginovart N., Vitcu I., Wilson A.A., Zipursky R.B., Kapur S. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007, 32(6):1209-1215.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, APA, Washington, DC. 4th.
4. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18:63-101.
5. Attarbaschi T., Sacher J., Geiss-Granadia T., Klein N., Mossaheb N., Lanzenberger R., Asenbaum S., Dudczak R., Kasper S., Tauscher J. Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. European Neuropsychopharmacology 2007, 17(2):102-1077.
6. Bigliani V., Mulligan R.S., Acton P.D., Ohlsen R.I., Pike V.W., Ell P.J., Gacinovic S., Kerwin R.W., Pilowsky L.S. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2000, 150(2):132-140.
7. Catafau A.M., Corripio I., Pérez V., Martin J.C., Schotte A., Carrió I., Alvarez E. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Research: Neuroimaging 2006, 148(2-3):175-183.
8. Corripio I., Catafau A.M., Perez V., Puigdemont D., Mena E., Aguilar Y., Carrio I., Alvarez E. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progress in Neuropsychopharmacology and Biological Psychiatry 2005, 29(1):91-96.
9. Dresel S., Tatsch K., Dähne I., Mager T., Scherer J., Hahn K. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in risperidone-treated schizophrenic patients. Journal of Nuclear Medicine 1998, 39(7):1138-1142.
10. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry 1988, 45(1):71-76.
11. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry 1992, 49:538-544.
12. Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone treated schizophrenic patients. Journal of Clinical Psychopharmacology 1995, 15(1 Suppl 1):19S-23S.
13. Gao K., Kemp D.E., Ganocy S.J., Gajwani P., Xia G., Calabrese J.R. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. Journal of Clinical Psychopharmacology 2008, 28(2):203-209.
14. Guardia J., Catafau A.M., Batlle F., Martín J.C., Gonzalvo B., Segura L., Prat G., Carrió I., Casas M. Striatal dopaminergic D2 receptor density measured by [123I]Iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. American Journal of Psychiatry 2000, 157:127-129.
15. Kapur S. Modulation of dopamine D2 receptors as a basis of antipsychotic effect. Dopamine in the Pathophysiology and Treatment of Schizophrenia 2003, 49-67. Martin Dunitz, London. S. Kapur, Y. Lecrubier (Eds.).
16. Kapur S., Seeman P. Does fast disassociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry 2001, 158:360-369.
17. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 1999, 156(2):286-293.
18. Kapur S., Zipursky R., Jones C., Gary R., Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 2000, 157:514-520.
19. Kasper S., Tauscher J., Küfferle B., Barnas C., Hesselman B., Asenbaum S., Podreka I., Brück T. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. Psychopharmacology (Berl) 1998, 136(4):367-373.
20. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
21. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., Meltzer H.Y. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 2005, 30(12):2283-2289.
22. Klemm E., Grunwald F., Kasper S., Menzel C., Broich K., Danos P., Reichmann K., Krappel C., Rieker O., Briele B., Hotze A.L., Moller H.J., Biersack H.J. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. American Journal of Psychiatry 1996, 153:183-190.
23. Knable M.B., Heinz A., Raedler T., Weinberger D.R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Research: Neuroimaging 1997, 75(2):91-101.
24. Lambert T.J., Castle D.J. Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia 2003, 178:S57-S61. (Suppl).
25. Mamo D., Kapur S., Shammi C.M., Papatheodorou G., Mann S., Therrien F., Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. American Journal of Psychiatry 2004, 161:818-825.
26. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacology Bulletin 1989, 25:390-392.
27. Nguyen N., Pradel V., Micallef J., Montastruc J.L., Blin O. Drug-induced Parkinson syndromes. Therapie 2004, 59(1):105-112.
28. Pappa S., Dazzan P. Spontaneous movement disorders in antipsychotic-naïve patients with first-episode psychoses: a systematic review. Psychological Medicine 2009, 39(7):1065-1076.
29. Perez V., Catafau A.M., Corripio I., Martin J.C., Alvarez E. Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Progress in Neuropsychopharmacology and Biological Psychiatry 2003, 27(5):767-770.
30. Pilowsky L.S., Costa D.C., Ell P.J., Murray R.M., Verhoeff N.P., Kerwin R.W. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychological Medicine 1993, 23(3):791-797.
31. Pilowsky L.S., Mulligan R.S., Acton P.D., Ell P.J., Costa D.C., Kerwin R.W. Limbic selectivity of clozapine. Lancet 1997, 350:490-491.
32. Pohjalainen T., Rinne J.O., Någren K., Syvälahti E., Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. American Journal of Psychiatry 1998, 155(6):768-773.
33. Raedler T.J., Knable M.B., Lafargue T., Urbina R.A., Egan M.F., Pickar D., Weinberger D.R. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Research 1999, 90(2):81-90.
34. Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002, 47(1):27-38.
35. Stahl S.M. Stahl's Essential Psychopharmacology 2008, Cambridge University Press, New York (NY). 3ed.
36. Stephenson C.M., Bigliani V., Jones H.M., Mulligan R.S., Acton P.D., Visvikis D., Ell P.J., Kerwin R.W., Pilowsky L.S. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. British Journal of Psychiatry 2000, 177:408-415.
37. Stone J.M., Davis J.M., Leucht S., Pilowsky L.S. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs-an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophrenia Bulletin 2009, 35(4):789-797.
38. Tatsch K., Asenbaum S., Bartenstein P., Catafau A., Halldin C., Pilowsky L.S., Pupi A. European association of nuclear medicine procedure guidelines for brain neurotransmission SPET using(123)I-labelled dopamine D(2) receptor ligands. European Journal of Nuclear Medicine and Molecular Imaging 2002, 29:23-29.
39. Tauscher J., Küfferle B., Asenbaum S., Fisher P., Pezawas L., Barnas C., Tauscher-Wisniewsky S., Brücke T., Kasper S. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 1999, 141:175-181.
40. Tauscher J., Küfferle B., Asenbaum S., Tauscher-Wisniewsky S., Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 2002, 162:42-49.
41. Thanvi B., Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgraduate Medical Journal 2009, 85(1004):322-326.
42. Trichard C., Paillère-Martinot M.-L., Attar-Levy D., Recassens C., Monnet F., Martinot J.-L. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. American Journal of Psychiatry 1998, 155:505-508.
43. Volkow N.D., Gur R.C., Wang G., Fowler J.S., Moberg P.J., Ding Y., Hitzemann R., Smith G., Logan J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. American Journal of Psychiatry 1998, 155:344-349.
44. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects 2000, World Medical Association, Ferney-Voltaire, France. http://www.wma.net/e/policy/b3.htm.
45. Xiberas X., Martinot J.L., Mallet L., Artiges E., Loc'H C., Mazière B., Paillère-Martinot M.L. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 2001, 179:503-508.